Post-Birth sugar check reveals hidden diabetes risk in moms
NCT ID NCT01839448
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 500 women who had gestational diabetes during pregnancy. They took a glucose test 4 to 12 weeks after giving birth to see how many had type 2 diabetes, impaired glucose tolerance, or impaired fasting glucose. The goal was to compare women diagnosed with gestational diabetes before 24 weeks of pregnancy versus those diagnosed after 24 weeks. The study does not test a treatment but aims to improve understanding of postpartum diabetes risk.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could help doctors better understand when to screen for diabetes after pregnancy, leading to earlier detection and prevention of type 2 diabetes.
- What could go wrong
- This is an observational study, not a treatment trial. It only measures outcomes without testing any intervention, so it cannot directly improve health. Results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
500 people
The number who actually took part.
- Started
-
Mar 2014
- Finished
-
Oct 2016
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population is composed of pregnant women consulting before 24 weeks of amenorrhea and who have at least one of the following risk factors: age \> 35 years; body mass index \> 25; a family history of type 2 diabetes; a history of gestational diabetes or macrosomia.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * The patient must have given her informed and signed consent * The patient must be insured or beneficiary of a health insurance plan * The patient is available for 10 months of follow-up * The patient is pregnant and consulting before 24 weeks of amenorrhea AND has at least one of the following risk factors: age \> 35 years; body mass index \> 25; family history of type 2 diabetes; history of gestational diabetes; history of macrosomia. * The patient has a fasting blood glucose level \>= 0.92 g/l before 24 weeks of amenorrhea OR a fasting blood glucose level \< 0.92 g/l before 24 weeks of amenorrhea AND an abnormal oral glucose tolerance test (75 g of glucose) between 24 and 28 weeks of amenorrhea (normal values are set at T0 \< 0.92 g/l; T60 \< 1.80 g/l; T120 \< 1.53 g/l). Exclusion Criteria: * The patient is participating in another study * The patient is in an exclusion period determined by a previous study, with the exception of the following studies: Papillo PMA (RCB 2013-A00538-37), LXRs (RCB 2009-A00968-49), GrossPath (RCB 2014-A01120-47), BAKRI (RCB 2013-A00914-41), OASIS II (RCB 2013-A00773-42), ElastoMAP (RCB 2013-A01148-37), ElastoDéclench (RCB 2014-A00828-39) and UpSideDown (RCB 2014-A01921-46). * The patient is under judicial protection, under tutorship or curatorship * The patient refuses to sign the consent * It is impossible to correctly inform the patient * The patient cannot read French * The patient has a known history of type 2 diabetes * The patient is diagnosed with type 2 diabetes during pregnancy (fasting blood glucose level \> 1.26 g/l) * The patient has a contra-indication for a treatment necessary for this study * The patient is taking chronic or intermittent oral or inhaled corticosteroids, or a β2 agonist treatment for a previous disease or a disease discovered during pregnancy within one week preceding the fasting glucose or oral glucose tolerance test.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gestational diabetes are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CH d'Arles - Hôpital Joseph Imbert
Arles, 13637, France
-
CHU de Montpellier - Hôpital Arnaud de Villeneuve
Montpellier, 34295, France
-
CHU de Montpellier - Hôpital Lapeyronie
Montpellier, 34295, France
-
CHU de Nîmes - Hôpital Universitaire Carémeau
Nîmes, 30029, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can mindfulness and yoga rewire diabetes habits?
- Can a vegan diet delivered online help people with type 2 diabetes?
- Tiny horses, big lessons: can ponies help kids tame diabetes?
- Gut microbes in pregnancy and infancy: a window into lifelong health?
- A blood test at 50 could flag your risk of five diseases. can an app stop them?
- Can a social media platform help manage gestational diabetes?